AT-Patch (ATP-C130/ATP-C70) vs CT Cardiomegaly
AI Verdict
Choose AT-Patch (ATP-C130/ATP-C70) if…
Choose AT-Patch if you require continuous, long-term cardiac monitoring for patients in an ambulatory setting, particularly when intermittent arrhythmias are suspected or extended observation is needed. Its wearable, shower-proof design and up to 14 days of monitoring without intervention make it ideal for capturing elusive cardiac events while maintaining patient comfort and daily activities.
View AT-Patch (ATP-C130/ATP-C70) →Choose CT Cardiomegaly if…
Choose CT Cardiomegaly if your workflow involves analyzing existing CT chest images and you need an automated, quantitative tool to assess for cardiomegaly. This command-line software efficiently provides precise cardiothoracic ratio measurements, assisting radiologists and cardiologists in detecting cardiac enlargement from imaging data.
View CT Cardiomegaly →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AT-Patch (ATP-C130/ATP-C70) | CT Cardiomegaly |
|---|---|---|
| Pricing | N/a | Contact for pricing |
| Deployment | Wearable device for patients; analysis software deployed on-premise at medical institutions. | Docker Container (Ubuntu 20.04), command-line software |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AT-Patch (ATP-C130/ATP-C70)AT-Patch offers a patient-friendly wearable device that is compact, lightweight, shower-proof, and requires no charging or electrode replacement during its 14-day monitoring period. It also includes a smartphone app for live ECG viewing and symptom recording, making it highly accessible for patients, while also providing dedicated analysis software for clinicians. In contrast, CT Cardiomegaly is a command-line software, which typically implies a higher technical barrier for users compared to a device with a dedicated app and analysis interface.
Clinical Value
TieBoth tools provide significant clinical value in their respective domains. AT-Patch offers crucial long-term continuous ECG monitoring and AI-powered arrhythmia detection, which is vital for diagnosing intermittent cardiac events. CT Cardiomegaly enhances the efficiency and objectivity of cardiomegaly detection in radiology by providing automated, quantitative measurements validated against manual assessments. Without specific comparative clinical outcome data across different disease states, it is difficult to declare one superior in overall clinical value.
Pricing & Value
TieNeither tool provides publicly available pricing information, with both requiring direct contact for details. This lack of transparency makes it impossible to conduct a head-to-head comparison of their costs or to assess their respective value propositions in terms of potential cost savings or return on investment for healthcare institutions.
Enterprise Readiness
CT CardiomegalyTool B (CT Cardiomegaly) explicitly states it is HIPAA compliant and that a Business Associate Agreement (BAA) is typically offered, which are critical assurances for enterprise adoption in healthcare. Its deployment as a Docker container is also a standard and scalable approach for IT departments. While Tool A (AT-Patch) is FDA-cleared and likely HIPAA compliant, the lack of explicit BAA mention and a 'likely' HIPAA status makes Tool B's readiness more clearly defined for enterprise environments.
Innovation
AT-Patch (ATP-C130/ATP-C70)AT-Patch demonstrates a broader scope of innovation by integrating a robust, patient-friendly wearable device capable of up to 14 days of continuous, shower-proof monitoring with advanced AI/machine learning algorithms for ECG analysis. This combination of novel hardware and intelligent software for a critical diagnostic function represents a more comprehensive innovative approach. CT Cardiomegaly, while innovative in its application of AI for automated cardiothoracic ratio measurement, focuses primarily on software automation of a specific radiological task.
Support & Docs
AT-Patch (ATP-C130/ATP-C70)AT-Patch has clearly accessible user manuals, quick guides, and PC software documentation publicly available online, providing comprehensive support for both patients and clinicians. In contrast, public documentation for Innolitics' CT Cardiomegaly appears to be limited to technical specifications and regulatory filings, without easily discoverable user-facing support materials.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AT-Patch (ATP-C130/ATP-C70) | CT Cardiomegaly |
|---|---|---|
| Name | AT-Patch (ATP-C130/ATP-C70) | CT Cardiomegaly |
| Company | ATsens Co. | Innolitics |
| Description | FDA-cleared wearable ECG monitor offering up to 14 days of continuous cardiac monitoring with high accuracy, a shower-proof design, and integrated AI-powered analysis software for enhanced arrhythmia detection. | FDA-cleared AI-powered command-line software that automatically measures cardiothoracic ratio from CT chest images, assisting physicians in cardiomegaly detection with quantitative data. |
| Categories | Cardiology AI, Wearables & Remote Monitoring (RPM) | Cardiology AI, Radiology & Imaging AI |
| Specialties | Cardiology, Family Medicine, Internal Medicine | Cardiology, Radiology |
| Key Features (Example) | Up to 14 days of continuous ECG monitoring (ATP-C130), Shower-proof design (IP57 for ATP-C130, IP44 for ATP-C70), AT-Report software with AI/machine learning algorithms for ECG analysis | Automatic cardiothoracic ratio measurement, Segmentation of heart and thoracic cavity, Outputs PDF and JSON reports |
Videos
Demos, reviews, and walkthroughs featuring AT-Patch (ATP-C130/ATP-C70) and CT Cardiomegaly.